The Case for Global Health: Prioritizing High-Impact Disease Interventions

Executive Summary

Global health stands apart from virtually every other cause area in one critical respect: we already know how to save lives at scale. The tools exist. The evidence is overwhelming. What remains scarce is sustained, strategically allocated funding and political will. This report makes the case that global health — particularly the prevention of infectious disease in low-income countries — remains one of the highest-impact opportunities available to individuals, institutions, and governments seeking to reduce suffering.

The Scale of the Problem

Approximately 13 million people die each year from communicable diseases, maternal causes, neonatal conditions, and nutritional deficiencies — the vast majority in low- and middle-income countries (LMICs). Malaria alone claims roughly 600,000 lives annually, over 75% of them children under five. Tuberculosis kills 1.3 million people per year and infects 10 million more. Neglected tropical diseases (NTDs) — including schistosomiasis, lymphatic filariasis, and trachoma — afflict over one billion people, causing disability, poverty traps, and preventable death.

These numbers represent not just mortality but an immense burden of morbidity: children who cannot attend school due to parasitic infections, adults too ill to work, communities whose productive potential is systematically eroded by preventable disease.

Why This Is Tractable

Unlike many of the world's hardest problems, the tractability of global health interventions is exceptional:

• Insecticide-treated bednets (ITNs): Distribution programs have been shown in randomized controlled trials to reduce child mortality by 17–30% in endemic regions. GiveWell estimates a cost of roughly $3,000–$5,000 per life saved through top-performing malaria charities.
• Oral rehydration therapy (ORT): A simple mix of salts and sugar that prevents death from diarrheal disease — the second-leading cause of child death globally — costs less than $0.50 per treatment.
• Vitamin A supplementation: Semi-annual supplementation for children 6–59 months reduces all-cause mortality by 12–24% in deficient populations, at a cost of approximately $1 per child per year.
• Vaccines: The measles vaccine prevents approximately one million deaths per year. HPV vaccines can prevent nearly all cervical cancer cases if deployed at scale.

The Neglectedness Gap

Despite this evidence, global health is dramatically underfunded relative to its impact. The entire budget of the global malaria response is roughly $4 billion per year — less than the revenue of a mid-sized pharmaceutical company. Meanwhile, wealthy-country health systems spend thousands of dollars per quality-adjusted life year (QALY) saved on interventions orders of magnitude less cost-effective.

This gap is structural: political incentives favor domestic constituents; media coverage favors dramatic, visible disasters over the slow grind of endemic disease; and the people most affected have little political voice in donor countries.

Recommendations

1. Prioritize organizations with strong evidence bases: GiveWell top charities (e.g., Against Malaria Foundation, Malaria Consortium, Helen Keller International) have the strongest cost-effectiveness track records.
2. Advocate for increased LMIC health system funding through multilateral mechanisms (Gavi, the Global Fund, World Bank IDA windows).
3. Support research into next-generation interventions including malaria vaccines (RTS,S, R21), tuberculosis vaccines, and antimicrobial resistance mitigation.
4. Use ITN metrics as a tractability benchmark when evaluating other cause areas — if an intervention costs more than $10,000 per life saved, it should face rigorous justification.

Further Reading

• GiveWell Top Charities (givewell.org)
• WHO World Health Statistics 2024
• DCP3 (Disease Control Priorities, 3rd Edition)
• Jamison et al., "Global Health 2035," The Lancet (2013)